1-Cocaine cas no:50-36-2

Name1-Cocaine
CAS50-36-2
Synonyms(1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate;1-alpha-H,5-alpha-H-Tropane-2-beta-carboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate;2-beta-Carbomethoxy-3-beta-benzoxytropane;2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester);2beta-Carbomethoxy-3beta-benzoxytropane;3-(Benzoyloxy)-8-methyl-8-azabicyclo-(3.2.1)octane-2-carboxylic acid methyl ether;3-Tropanylbenzoate-2-carboxylic acid methyl ester;3beta-Hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylic acid methyl ester benzoate;8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))-;Benzoylmethylecgonine
EINECS(EC#)200-032-7
Molecular FormulaC17H21 N O4
Molecular Weight303.39

AppearanceWhite powder
refractive index1.568
storage temp2-8°C

Hazardclass6.1(a)

Hazard CNS stimulant, a poison. Possession is illegal in U.S.
Risk 23/24/25-43
Safety

A human poison by ingestion and possibly other routes. Poison experimentally by ingestion, intraperitoneal, intravenous, subcutaneous, and parenteral routes. Human central nervous system effects by ingestion and possibly other routes: general anesthesia, hallucinations or distorted perceptions, and convulsions. An eye irritant. A widely abused, controlled substance. Abuse leads to habituation or addiction. In medicine, it is used as a local narcotic anesthetic applied topically to mucous membranes. The free base is soluble in fats and thus is used for ointments and oily solutions. For water-soluble applications, the sulfate or hydrochloride is used. When heated to decomposition it emits highly toxic fumes.
Hazard Codes: T
Risk Statements: 23/24/25-43
 R23/24/25:Toxic by inhalation, in contact with skin and if swallowed. 
R43:May cause sensitization by skin contact.
Safety Statements: 26-36/37-45-36/37/39-22 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36/37:Wear suitable protective clothing and gloves. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S22:Do not breathe dust.
RIDADR: UN 1648 3/PG 2
WGK Germany: 3
RTECS: YM2800000
HazardClass: 6.1(a)
PackingGroup: II

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LDLo	intravenous	7500ug/kg (7.5mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC	"Nachprufung der Toxicitat von Novocain und Tutocain bei Chloralisierten Tieren, Dissertation," Barke, A., Pharmakologischen Institut der Tierarztlichen Hochschule zu Hannover, Fed. Rep. Ger., 1936Vol. -, Pg. -, 1936.
cat	LDLo	subcutaneous	16mg/kg (16mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC	"Nachprufung der Toxicitat von Novocain und Tutocain bei Chloralisierten Tieren, Dissertation," Barke, A., Pharmakologischen Institut der Tierarztlichen Hochschule zu Hannover, Fed. Rep. Ger., 1936Vol. -, Pg. -, 1936.
cattle	LDLo	subcutaneous	180mg/kg (180mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1332, 1935.
chicken	LDLo	subcutaneous	120mg/kg (120mg/kg)		"Ueber die Wirkung Verschiedener Gifte Auf Vogel, Dissertation," Forchheimer, L., Pharmakologischen Institut der Universitat Wurzburg, Fed. Rep. Ger., 1931Vol. -, Pg. -, 1931.
dog	LD50	intravenous	13mg/kg (13mg/kg)	AUTONOMIC NERVOUS SYSTEM: SYMPATHOMIMETIC BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 235, Pg. 328, 1978.
dog	LDLo	subcutaneous	3500ug/kg (3.5mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC	"Nachprufung der Toxicitat von Novocain und Tutocain bei Chloralisierten Tieren, Dissertation," Barke, A., Pharmakologischen Institut der Tierarztlichen Hochschule zu Hannover, Fed. Rep. Ger., 1936Vol. -, Pg. -, 1936.
domestic animals - goat/sheep	LDLo	subcutaneous	180mg/kg (180mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1332, 1935.
frog	LDLo	intraspinal	175mg/kg (175mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 45, Pg. 291, 1932.
frog	LDLo	subcutaneous	300mg/kg (300mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: EXCITEMENT CARDIAC: PULSE RATE	Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 144, Pg. 197, 1929.
guinea pig	LD50	subcutaneous	31mg/kg (31mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 240, Pg. 523, 1961.
guinea pig	LDLo	intravenous	20mg/kg (20mg/kg)		Physiological Reviews. Vol. 12, Pg. 190, 1932.
human	TCLo	inhalation	3571ug/kg (3.571mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Annals of Emergency Medicine. Vol. 21, Pg. 772, 1992.
human	TDLo	intravenous	1786ug/kg (1.786mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Annals of Emergency Medicine. Vol. 21, Pg. 772, 1992.
human	TDLo	oral	714mg/kg (714mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	JAMA, Journal of the American Medical Association. Vol. 238, Pg. 1391, 1977.
infant	TDLo	intrapleural	2308ug/kg (2.308mg/kg)	BEHAVIORAL: EXCITEMENT LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Journal of Toxicology, Clinical Toxicology. Vol. 25, Pg. 419, 1987.
infant	TDLo	oral	25800ng/kg (0.0258mg/kg)	BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP BEHAVIORAL: IRRITABILITY	Pediatric Emergency Care. Vol. 8, Pg. 82, 1992.
man	LDLo	oral	7353ug/kg (7.353mg/kg)		"Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
man	TCLo	inhalation	7143ug/kg (7.143mg/kg)	BEHAVIORAL: IRRITABILITY GASTROINTESTINAL: NAUSEA OR VOMITING KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION	Lancet. Vol. 2, Pg. 1150, 1987.
man	TDLo	intravenous	14mg/kg/4D-I (14mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION	American Journal of Medicine. Vol. 81, Pg. 699, 1986.
mouse	LD50	intraperitoneal	59mg/kg (59mg/kg)		Klinische Wochenscrift. Vol. 31, Pg. 97, 1953.
mouse	LD50	intravenous	16mg/kg (16mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 1275, 1966.
mouse	LD50	oral	99mg/kg (99mg/kg)	BEHAVIORAL: EXCITEMENT BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 1275, 1966.
mouse	LD50	subcutaneous	81mg/kg (81mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: EXCITEMENT	Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 1025, 1966.
mouse	LD50	unreported	108mg/kg (108mg/kg)		Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 53, Pg. 2S, 1957.
pigeon	LDLo	subcutaneous	60mg/kg (60mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1333, 1935.
rabbit	LD50	intravenous	17mg/kg (17mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 15, Pg. 731, 1930.
rabbit	LD50	unreported	20mg/kg (20mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 1957, 1974.
rabbit	LDLo	oral	126mg/kg (126mg/kg)		"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 78, 1973.
rabbit	LDLo	subcutaneous	50mg/kg (50mg/kg)		Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 160, Pg. 53, 1931.
rat	LD50	intraperitoneal	70mg/kg (70mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 15, Pg. 731, 1930.
rat	LD50	intravenous	17500ug/kg (17.5mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 15, Pg. 731, 1930.
rat	LD50	subcutaneous	250mg/kg (250mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 15, Pg. 731, 1930.
women	TCLo	inhalation	14600mg/kg/2Y (14600mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION LUNGS, THORAX, OR RESPIRATION: DYSPNEA	American Journal of Medicine. Vol. 81, Pg. 699, 1986.
women	TDLo	intravenous	10mg/kg (10mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS MUSCULOSKELETAL: OTHER CHANGES	American Journal of Medicine. Vol. 85, Pg. 579, 1988.